



BAUS

SECTION OF ONCOLOGY
MEETING

PROGRAMME

ICC WALES



2-3 OCTOBER 2025



General Information

Address

International Convention Centre Wales
The Coldra
Caerleon
Newport
NP18 1HQ

Access

The conference will be held in Meeting Room 1D. The exhibition and refreshments will take place in Meeting Room 1E. Registration will be located outside Meeting Room 1E.

Badges

All delegates, speakers, exhibitors and staff should wear their badge for security reasons during the meeting. Access to the conference and exhibition may be denied to people not wearing badges.

Car Parking

Car parking can be pre-booked in advanced or paid for on the day of your visit.

Directions to the International Convention Centre

Located just off Junction 24 of the M4 Moterway, ICC Wales is within easy reach whether you choose to travel by car, public transport or on foot.

Get directions and full address details below.

<https://www.iccwales.com/getting-here>

General Information

CME Points

The following CME points will be available for this meeting:

Thursday 2nd October: 6 Points

Friday 3rd October: 6 Points

Facilities

ICC Wales has fully accessible toilets for both men and woman on every level.

Exhibition

The BAUS Section of Oncology is delighted to have received support from our trade partners and we hope you will take the opportunity to visit their stands.

BAUS Oncology 2025 is a sponsored event. All companies sponsoring the event are named and have no input into the content of the programme or the selection of speakers, except in the case of dedicated sponsored symposium sessions, which are clearly identified in the conference programme. BAUS 2025 receives exhibition sponsorship from pharmaceutical companies and other trade partners.

There was no involvement in logistics, venue selection or any other meeting arrangements

Refreshments

Refreshments will be served alongside the exhibition in Meeting Room 1E. Any delegate who has advised of any dietary requirements will find that these have been catered for.

General Information


Registration Desk

The registration desk will be open from the following times:

Thursday 2 October	08.30-17.30
Friday 3 October	08.30-16.30

Social Activities

The Conference Dinner will take place on Thursday 2 October.



Thursday 2 October

- 08.30 Registration and Arrival
- 09.15 Welcome to BAUS Oncology 2025
Vishwanath Hanchanale
- 09.30 Session 1: Optimising Prostate Cancer Care: From Diagnosis to Systemic Therapy
Chairs: **June Tay, Karthik Rajan and Manal Kumar**
- 09.30 Introduction and Welcome
- 09.33 Prostate Cancer Local Therapy: Are Focal and Radical Approaches Competing or Complementary?
Deepika Reddy
- 09.50 Navigating the Imaging Landscape in Prostate Cancer: Selecting the Right Modality for the Right Patient
Craig Jones
- 10.07 Perioperative Systemic Therapy in Radical Prostatectomy: Who, What, and When in the Era of Evolving Oncology Practice?
Ashwin Sachdeva
- 10.24 Active Surveillance in Cambridge Prognostic Group 2 Prostate Cancer: Safety, Selection Criteria, and Surveillance Protocols
Vincent Gnanapragasam
- 10.41 Urologists Prescribing Androgen Receptor Pathway Inhibitors in mHSPC: What Do We Need to Know?
Noel Clarke
- 10.58 Summary and Closing Remarks
- 11.00 Refreshments, Poster & Exhibition Viewing
- 11.30 Session 2: The Big Urology Debates (BUD): Challenging Conventional Wisdom in Urologic Oncology
Chairs: **Tharani Nitkunan, Chidi Molokwu and Ben Ayres**

Thursday 2 October

- 11.30 Introduction and Overview
- 11.33 Debate 1: Should Digital Rectal Examination Remain a Gatekeeper in Suspected Prostate Cancer Referrals?
Caroline Moore and Ben Lamb
- 11.55 Debate 2: Can Most Bosniak III Cysts be Monitored?
Hosam Serag and Ravi Barod
- 12.17 Debate 3: Should Most Suspected Upper Tract Urothelial Carcinoma Cases Undergo Diagnostic Ureteroscopy?
Dominguez Escrig Jose Luis and Bhavan Rai
- 12.38 Conclusion and Audience Voting
- 12.40 Commercial Break - MSD
- 12.45 Lunch, Poster & Exhibition Viewing
- 13.45 Session 3: Bladder Cancer Today: Risks, Imaging, and Evolving Treatments
Chairs: **Elsie Mensah, Rami Issa and Parag Sonawane**
- 13.45 Introduction and Welcome
- 13.48 Unpacking the Risks: Non-Smoking Factors Contributing to Urothelial Cancer
Gareth Collett
- 13.58 Novel therapies for BCG refractory High-Risk Non-Muscle-Invasive Bladder Cancer: Emerging Evidence and Key Clinical Trials
Dominguez Escrig Jose Luis
- 14.21 MRI-Based Pathways for Radical Treatment of MIBC: Ready for Prime Time?
Richard Bryan
- 14.38 Current Perspectives on Managing Clinically Node-Positive MIBC
Alison Birtle

Thursday 2 October

- 14.55 Managing the Frail Bladder Cancer Patient: Can We Take a Realistic Approach?
Babbin John
- 15.15 Commercial Break - Medac
- 15.20 Refreshments, Poster & Exhibition Viewing
- 15.45 Session 4: Contemporary Techniques in Urologic Oncology: Video Demonstrations and Expert Insights
Chairs: **James Armitage, Jim Wilson and Eva Bolton**
- 15.45 Introduction and Welcome
- 15.48 SpaceOAR Hydrogel Placement for Prostate Radiotherapy and focal therapy: Stepwise Technique
Tim Dudderidge
- 15.58 Transperineal Prostate Biopsy Without a Rectum: Technique
Edgar Paez
- 16.08 Single-Port Robotic Partial Nephrectomy: Procedural Overview
Ben Challacombe
- 16.24 Navigating the Challenging Partial Nephrectomy: Expert Techniques in Robotic Surgery
Patricia Zondervan
- 16.40 Robotic Salvage Radical Prostatectomy: Technical Pearls and Outcomes
Senthil Nathan
- 16.56 Panel Discussion and Closing Remarks
- 16.56 Commercial Break - Nonacus

Friday 3 October

- 08.00 Poster Session 1
Chairs: **Eva Bolton, Ramanan Rajasundaram, Adam Bennett**
- 09.00 Session 5: Modern Management of Upper Tract and Renal Cancer: Controversies and Emerging Evidence
Suresh Venugopal, Neil Fenn and Sarika Nalagatla
- 09.00 Introduction
- 09.03 Are We Ready for Next-Generation Biomarkers in Kidney Cancer? KIM-1 and the GAGome
Tom Mitchell
- 09.18 Multifocal Localized RCC: Surgical Strategies, Biopsy, ablation, Surveillance, and the Emerging Role of Belzutifan – an Algorithmic Approach
Alex Laird
- 09.33 Neoadjuvant Systemic Options Prior to Radical Nephrectomy
Faiz Mumtaz
- 09.48 Who Benefits Most from Upfront Cytoreductive Nephrectomy? A Decision-Making Framework
Patricia Zondervan
- 10.08 Research in Surgical Renal Cancer: Is Our Cup Partially Full?
Rakesh Heer
- 10.23 Conclusion
- 10.25 Commercial Break- MSD/AZ
- 10.30 Refreshments, Poster & Exhibition Viewing
- 11.00 Session 6: Best of British Research
Chairs: **Joe Philip, Cristian Llie and Elizabeth Bright**
- 11.00 Introduction

Friday 3 October

- 11.03 Updates on STAMPEDE and NPCA
Noel Clarke
- 11.18 Renal cancer trials & NKCA update
Raghav Varma
- 11.33 Bladder / Urothelial Cancer Research in UK
Niyati Lobo
- 11.48 Prostate Cancer Research – British Landscape
Prabhakar Rajan
- 12.03 Conclusion
- 12.05 Commercial Break - Bayer
- 12.10 Session 7: Poster Session 2 & Video Presentations
Sarah Prattley, Nic Bullock and Tom Dutton
- 13.10 Lunch, Poster & Exhibition Viewing
- 14.00 Session 8: Pathways and Surgical Planning in Urologic Oncology
Chairs: **Shiv Pandian, Krishna Narahari and Jelizaveta Pereca**
- 14.00 Introduction
- 14.02 MRI-Guided Preoperative Planning for Precision Radical Prostatectomy – The COMPASS Initiative
Zaf Tandogdu
- 14.16 Application of AI in Surgical Planning – Trends and Future Directions
Nik Vasdev
- 14.30 Management of Small Testicular Masses
Suks Minhas

Friday 3 October

- 14.44 The Bladder Scheduling Meeting: Customising NMIBC Surgery
Helena Burden
- 14.58 Conclusion
- 15.00 Refreshments, Poster & Exhibition Viewing
- 15.30 Session 9: Next Generation Uro-Oncology: Bridging Training, Practice, and Technology
Chairs: **Waleed Elsayed** and **Sarika Nalagatla**
- 15.30 Introduction by Chairs
- 15.32 The Balancing Act: Advanced Uro-Oncology Training through the Eyes of a Trainer
Sotonye Tolofari
- 15.46 Academic Urology in Practice: A Trainee's Role in GIRFT and National Guidance
Joseph John
- 16.00 Patient Engagement and Shared Decision-Making Uro-Oncology: A Trainee's Perspective
Madeline Moore
- 16.14 The AI Revolution: How Trainees Can Lead the Next Frontier in Uro-Oncology
Luis Ribeiro
- 16.28 Conclusions
- 16.30 Concluding Remarks